Five steps to ameliorate our illegal drug problem: One, focus on demand, not supply. Trying to stop the supply of drugs is a ...

IDEAYA Biosciences (NASDAQ:IDYA) said its lead oncology program remains on track for a regulatory submission after reporting positive top-line data in first-line metastatic melanoma, while also highli ...

Compugen (CGEN) is maintained at a Buy rating, driven by advancing clinical programs and upcoming catalysts in oncology.

Medicare drug changes in 2026 may raise costs, alter formularies, and add prior authorization. Learn how your medicines and ...

The Searchlight Institute wants Democrats to shake up their approach to healthcare and offer a fresh vision for the future.

Key highlights from the first quarter of operations under the expanded management team include the following: Anticipated FDA ...

Key highlights from the first quarter of operations under the expanded management team include the following: Anticipated FDA decision on the Company's ANDA for Preservative-Free Ketamine in Q3 2026 ...

The 2025 American Lung Association’s “State of Tobacco Control” report was recently released. It finds that federal and state ...

Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed ...

Iopofosine I-131 achieved an overall response rate of 83.6% and a major response rate of 61.8% in patients with relapsed or ...

In the area of tobacco control, there were virtually no positive developments at the federal level in 2025; state performance ...